Marshall Wace
BCRX icon

Marshall Wace’s BioCryst Pharmaceuticals BCRX Stock Holding History

Marshall Wace’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.53M Buy
252,764
+6,287
+3% +$56.9K ﹤0.01% 1728
2026
Q1 		$2.35M Buy
+246,477
New +$1.91M ﹤0.01% 1696
2025
Q4 		– Sell
-731,411
Closed -$5.55M – 2961
2025
Q3 		$5.55M Buy
731,411
+588,099
+410% +$4.9M 0.01% 1146
2025
Q2 		$1.28M Buy
+143,312
New +$1.33M ﹤0.01% 1757
2024
Q4 		– Sell
-33,257
Closed -$253K – 2583
2024
Q3 		$253K Buy
+33,257
New +$253K ﹤0.01% 2213
2023
Q4 		– Sell
-134,362
Closed -$951K – 2183
2023
Q3 		$951K Buy
+134,362
New +$965K ﹤0.01% 1517
2023
Q2 		– Sell
-126,699
Closed -$1.06M – 2473
2023
Q1 		$1.06M Buy
+126,699
New +$1.22M ﹤0.01% 1782
2022
Q3 		– Sell
-35,574
Closed -$376K – 3341
2022
Q2 		$376K Sell
35,574
-1,050,272
-97% -$10.8M ﹤0.01% 2929
2022
Q1 		$17.7M Buy
+1,085,846
New +$17.4M 0.03% 549
2021
Q2 		– Sell
-182,905
Closed -$1.86M – 2653
2021
Q1 		$1.86M Buy
+182,905
New +$1.89M 0.01% 1364
2020
Q3 		– Sell
-50,277
Closed -$239K – 1574
2020
Q2 		$239K Sell
50,277
-21,383
-30% -$85.4K ﹤0.01% 1374
2020
Q1 		$143K Buy
+71,660
New +$197K ﹤0.01% 1255
2014
Q3 		– Sell
-218,413
Closed -$2.79M – 879
2014
Q2 		$2.79M Buy
+218,413
New +$2.12M 0.04% 344

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Marshall Wace's BCRX Position: Q2 2026 in Review

Marshall Wace increased its BioCryst Pharmaceuticals (BCRX) stake by 2.6% in Q2 2026, buying an estimated $56.9K and bringing the position to 252,764 shares worth $2.53M. The position accounts for ﹤0.01% of the portfolio, ranked #1728.

Marshall Wace first reported a position in BCRX in Q2 2014 and has held it in 13 quarters since. The position peaked at $17.7M in Q1 2022. 319 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Marshall Wace held 252,764 shares of BioCryst Pharmaceuticals worth $2.53M as of Q2 2026.
  • Marshall Wace bought 6,287 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $56.9K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #1728 holding.
  • Marshall Wace first reported a position in BioCryst Pharmaceuticals in Q2 2014 and has held it in 13 quarters since.
  • Marshall Wace's BioCryst Pharmaceuticals position peaked at $17.7M in Q1 2022.
  • 319 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.